Page 55 - Pro-active Management of Women’s Health after Cardiometabolic Complicated Pregnancies

PSD rAPC
13.5% 7.1% 24.7% 16%
13% 9% 1.7% 3%
4% 3%
FVL PGM
HHC +/-, +/+
28.9% 5.0% 17.7%
+/-, +/+
2.9%
Country (Ethnicity)
Netherlands
Netherlands Israel
Netherlands
Italy, 100% Caucasian Netherlands
Germany
Italy, 100% Caucasian
Montreal, Canada Netherlands Netherlands
Japan
Hungary, 100% Cauc Israel, 44% Ashkenazi Italy, 100% Caucasian UK
Netherlands
Israel, 96% Ashkenazi
Israel, 25% Ashkenazi UK, 88% Caucasian France
Greece
Italy
Australia Italy
Ireland
Israel
US, 69% Cauc, 10% African Amer, 19% Hisp Sweden
Greece
Australia
Scotland
US, 31% Cauc, 34% African Amer, 33% Hisp
Special remarks
91% severe PE, 2*positive = positive
100% severe, FVL not yet known Placental parameters
SPE and/or IUGR <34w, 1*pos = pos 100% mild PE
100% early onset PE, 1*pos = pos; Only total thrombophilia factors compared 100% HELLP
60% severe PE, 2*pos = pos; Only total thrombophilia factors compared
?% severe PE
100% HELLP
100% PE without HELLP
36% severe PE 100% severe PE 100% severe PE
100% severe, 1*pos = pos Severe PE (n=55); PGM 9.1% Mild PE (n=25): PGM = 8.0% 100% Severe PE
100% Severe PE 35% Severe PE
PE+HELLP (n=32): FVL 15.6%, PGM 6.4% PE+IUGR (n=31): FVL 9.6%, PGM 3.2% 100% Severe PE
(only LAC, FVL, PGM)
57% 21%
3.2% 4.0%
17% 11%
16.9% 4.2%
11.7% 28.3%
20%
2.7% 13.0% 17%
18.8%
26.5% 5.9% 26.1%%
5.3%
8.8%
23.8% 7.9% 1.6%
18.8% 0.0% 7.2% 7.2%
8.3%
5.2% 1.7%
0.0%
3.7% 5.9%
0.0% 0.0% 7.0% 2.1%
4.7%
5.4% 14.3%
2.0% 3%
2.2 Associations between phenotypes of preeclampsia and thrombophilia| 53
PCD= Protein-C deficiency, PSD= Protein-S deficiency, rAPC= APC-resistance, HHC= hyperhomocysteineamia, MLT= methionine loading test, FVL= factor V Leiden, PGM= Prothrombine gene mutation)
5.0%
32.1% 11.3% 7.2%%
3.5% -
4.3% 26.1%
11.3% 12.1% 6.0%
7.9%
28.6%
5.1%
4.0%
4.7%